Following the deadline of late breaking abstract submission, 37 abstracts have been selected for the Presidential and proffered paper sessions. Due to a number of high quality abstracts, extra proffered paper sessions have been added:
- Immunotherapy of Cancer I, 09:15-10.25, 27 Sep
- Melanoma and Skin Cancer, 11.30-12.30, 27 Sep
- Early Drug Development II, 17:00-18:10, 27 Sep
Highlights of this year’s late breaking abstracts will include in the Presidential sessions:
Presidential session I
CheckMate 025: a randomised, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC); P. Sharma, B. Escudier, D.F. McDermott, S. George, H.J. Hammers, S. Srinivas, S.S. Tykodi, J.A. Sosman, G. Procopio, E.R. Plimack, D. Castellano1, H. Gurney, F. Donskov, P. Bono, J. Wagstaff, T.C. Gauler, T. Ueda, L.A. Xu, I.M. Waxman, R.J. Motzer
Metastatic Renal Cell Carcinoma has been seen as an immune responsive maglinancy, these results of the phase III will show that comparing nivolumab with everolimus in patients with previously treated metastatic renal cell carcinoma will change the treatment paradigm.
Presidential session II
177-Lu-Dotatate significantly improves progression-free survival in patients with mid gut neuroendocrine tumours: Results of the phase III NETTER-1 trial; J. Strosberg, E. Wolin, B. Chasen, M. Kulke, D. Bushnell, M. Caplin, R.P. Baum, E. Mittra, T. Hobday, A. Hendifar, K. Oberg, M. Lopera Sierra, P. Ruszniewski, D. Kwekkeboom
Reporting for the first time the results of NETTER-1, first Phase III multinational, randomised, controlled trial evaluating 177-Lu-Dotatate versus best standard of care in patients with inoperable, progressive, somatostatin receptor positive mid gut Neuroendocrine tumours. This population has currently very limited treatment options, these results will show an improved progression free survival for these patients.
Presidential III
5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group; D. Dearnaley, I. Syndikus, H. Mossop, A. Birtle, D. Bloomfield, C. Cruickshank, J. Graham, S. Hassan, V. Khoo, J. Logue, H. Mayles, J. Money-Kyrle, O. Naismith, M. Panades, H. Patterson, C. Scrase, J. Staffurth, J. Tremlett, C. Griffin, E. Hall
This potentially practice changing phase III clinical trial was conducted to evaluate the standard versus hypofractionated radiotherapy in men with localised prostate cancer. This is the largest randomised controlled treatment trial undertaken in this disease recruiting over 3200 participants. With a median of over 5 years follow-up, it is the first presentation of efficacy results from the trial.
The overview of the presidential sessions and late breaking proffered paper sessions can be found on the searchable programme.
(Please note all late breaking, best, oral and abstracts selected for the media programme will be available online only on the day of the presentation)
| |